Moderna Inc. stock gains on melanoma vaccine success and mixed analyst calls
Published on 09/19/2026 at 12:03 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Moderna Inc. stock (ISIN US60770K1079) traded at USD 158.07 on September 17, 2026 on Nasdaq, up 8.55% from the prior close of USD 145.62, as investors focused on the company’s positive Phase 3 melanoma vaccine data and a wave of new analyst price targets.
Cancer vaccine data drives Moderna Inc. stock
Catalyst for the latest move has been the Phase 3 readout for Moderna’s personalized mRNA cancer vaccine intismeran in melanoma, presented at the ESMO 2026 meeting and in a detailed trial report in mid-September 2026, which showed a 49% reduction in recurrence or death versus Merck’s immunotherapy Keytruda alone in certain high-risk patients, with a hazard ratio of 0.51 at five-year follow-up according to Pomegra.
According to Pomegra on September 18, 2026, Moderna stock rose about 9% to roughly USD 172 when the full Phase 3 dataset was presented, and the shares had gained about 143% over one month from roughly USD 63 before the August 19, 2026 announcement day, when the stock jumped 177% to close around USD 174.38.
Quarterly loss narrows but profitability remains distant
The strong share price momentum contrasts with still loss-making fundamentals. MarketBeat reported on September 17, 2026 that Moderna’s latest quarterly results for the period ended July 31, 2026 showed revenue of USD 145.0 million, which was up 2.1% compared with the same quarter a year earlier, while earnings per share came in at minus USD 1.97, beating the consensus forecast of minus USD 2.03 by USD 0.06 according to MarketBeat.
In the same July 31, 2026 quarter, Moderna posted a negative net margin of 141.43% and a negative return on equity of 28.30%, highlighting that the company remains far from profitability despite the narrower loss per share and modest top-line growth, as noted by MarketBeat.
Analyst targets for Moderna Inc. stock diverge widely
The Phase 3 success has triggered a broad reassessment among analysts, with targets that span a wide range and underscore the uncertainty around commercial uptake. Invezz reported on September 17, 2026 that Argus Research upgraded Moderna to Buy and set a price target of USD 180 per share, while Rothschild & Co downgraded the stock to Sell and simultaneously lifted its target to USD 81, reflecting sharply different risk-reward views, according to Ad-hoc-news.
The same Ad-hoc-news overview, citing analyst data compiled by MarketBeat on September 17, 2026, noted that Moderna carried an average rating of Hold and a consensus price target of USD 76.72, far below the prevailing share price in the USD 150 to USD 170 range, and listed individual calls such as CLSA at Outperform, Citi at Neutral with its target raised from USD 41 to USD 60, and Barclays raising its target from USD 48 to USD 125, all according to Ad-hoc-news.
Price levels and volatility around September 19, 2026
Recent trading has been volatile as the market digests both clinical success and the still-uncertain path to sustainable revenue. MarketBeat’s price history shows that Moderna closed at USD 158.07 on September 17, 2026 after a session range between USD 149.50 and USD 161.96, with the prior close at USD 145.62, implying an 8.55% daily gain, and that the shares traded in a 52-week range between USD 22.28 and USD 176.66 as of that date, based on data cited by MarketBeat.
According to the same MarketBeat chart overview on September 17, 2026, Moderna’s market capitalization stood at around USD 63.11 billion with trading volume of roughly 19.14 million shares, meaning the stock price of USD 158.07 was within about 10.5% of the 52-week high of USD 176.66, a relatively narrow gap considering the shares were trading near USD 22 at the 52-week low earlier in the period, as summarized by MarketBeat.
Next earnings date and expectations
Investors will soon get another look at Moderna’s financial trajectory. Zacks indicated on September 18, 2026 that the next earnings release for Moderna, covering the quarter ending in September 2026, is expected on November 5, 2026, with a consensus estimate of minus USD 1.36 per share and an anticipated year-over-year earnings decline of 166.67% for that quarter, according to Zacks.
The same Zacks earnings calendar noted that Moderna’s most recent quarterly report featured earnings of minus USD 1.97 per share, essentially in line with its own consensus estimate, and reiterated that analysts forecast a full-year 2026 earnings per share of minus USD 6.09, underlining that despite clinical progress and revenue guidance suggesting up to about 10% year-on-year growth from a roughly USD 3.5 billion 2025 base, the company is still expected to post a sizeable loss for the year, as outlined by Pomegra and MarketBeat.
Closing price context for Moderna Inc. stock
As of the most recent completed trading day referenced in the available data, September 17, 2026, Moderna Inc. stock closed at USD 158.07 on Nasdaq, with that price sitting well above the 52-week low of USD 22.28 and within striking distance of the 52-week high of USD 176.66, giving the company a market capitalization of roughly USD 63.11 billion on that date.
Moderna Inc. stock facts
- Company: Moderna Inc.
- ISIN: US60770K1079
- Ticker: MRNA
- Trading venue: Nasdaq
- Price (as of September 17, 2026): 158.07 USD
- Market capitalization: 63.11 billion USD (as of September 17, 2026)
- Sector / Industry: Biotechnology
- Index membership: S&P 500
- Next earnings date: November 5, 2026
